Bio-Rad Laboratories Inc (BIO-B) - Total Assets

Latest as of March 2026: $9.79 Billion USD

Based on the latest financial reports, Bio-Rad Laboratories Inc (BIO-B) holds total assets worth $9.79 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Bio-Rad Laboratories Inc service its debt to assess how comfortably operating cash covers total debt obligations.

Bio-Rad Laboratories Inc - Total Assets Trend (1985–2025)

This chart illustrates how Bio-Rad Laboratories Inc's total assets have evolved over time, based on quarterly financial data. See Bio-Rad Laboratories Inc shareholders equity for net asset value and shareholders' equity analysis.

Bio-Rad Laboratories Inc - Asset Composition Analysis

Current Asset Composition (December 2025)

Bio-Rad Laboratories Inc's total assets of $9.79 Billion consist of 27.5% current assets and 72.5% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 5.0%
Accounts Receivable $472.50 Million 4.5%
Inventory $740.70 Million 7.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $174.30 Million 1.7%
Goodwill $579.80 Million 5.5%

Asset Composition Trend (1985–2025)

This chart illustrates how Bio-Rad Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bio-Rad Laboratories Inc market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Bio-Rad Laboratories Inc's current assets represent 27.5% of total assets in 2025, a decrease from 75.4% in 1985.
  • Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, down from 8.4% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1985.
  • Asset Diversification: The largest asset category is inventory at 7.0% of total assets.

Bio-Rad Laboratories Inc Competitors by Total Assets

Key competitors of Bio-Rad Laboratories Inc based on total assets are shown below.

Company Country Total Assets
Edwards Lifesciences Corp
NYSE:EW
USA $13.32 Billion
DexCom Inc
NASDAQ:DXCM
USA $6.63 Billion
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
China CN¥805.10 Million
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
China CN¥1.86 Billion
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
China CN¥3.71 Billion
Theradiag SA
PA:ALTHE
France €11.55 Million
Corentec Co Ltd
KQ:104540
Korea ₩175.16 Billion
Adherium Ltd
AU:ADR
Australia AU$4.16 Million

Bio-Rad Laboratories Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.21 5.99 3.90
Quick Ratio 2.37 4.43 2.88
Cash Ratio 0.00 0.00 0.00
Working Capital $2.03 Billion $2.53 Billion $1.70 Billion

Bio-Rad Laboratories Inc - Advanced Valuation Insights

This section examines the relationship between Bio-Rad Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.16
Latest Market Cap to Assets Ratio 0.15
Asset Growth Rate (YoY) 12.9%
Total Assets $10.58 Billion
Market Capitalization $1.57 Billion USD

Valuation Analysis

Below Book Valuation: The market values Bio-Rad Laboratories Inc's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Bio-Rad Laboratories Inc's assets grew by 12.9% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Bio-Rad Laboratories Inc (1985–2025)

The table below shows the annual total assets of Bio-Rad Laboratories Inc from 1985 to 2025.

Year Total Assets Change
2025-12-31 $10.58 Billion +12.95%
2024-12-31 $9.36 Billion -23.86%
2023-12-31 $12.30 Billion -8.91%
2022-12-31 $13.50 Billion -24.15%
2021-12-31 $17.80 Billion +37.21%
2020-12-31 $12.97 Billion +61.98%
2019-12-31 $8.01 Billion +42.73%
2018-12-31 $5.61 Billion +31.31%
2017-12-31 $4.27 Billion +10.97%
2016-12-31 $3.85 Billion +3.80%
2015-12-31 $3.71 Billion +11.03%
2014-12-31 $3.34 Billion -1.40%
2013-12-31 $3.39 Billion -1.59%
2012-12-31 $3.44 Billion +11.20%
2011-12-31 $3.10 Billion +1.11%
2010-12-31 $3.06 Billion +20.78%
2009-12-31 $2.54 Billion +24.47%
2008-12-31 $2.04 Billion +3.33%
2007-12-31 $1.97 Billion +23.52%
2006-12-31 $1.60 Billion +11.89%
2005-12-31 $1.43 Billion +4.01%
2004-12-31 $1.37 Billion +38.18%
2003-12-31 $992.60 Million +37.73%
2002-12-31 $720.70 Million +5.36%
2001-12-31 $684.03 Million +5.84%
2000-12-31 $646.28 Million -3.38%
1999-12-31 $668.90 Million +82.11%
1998-12-31 $367.30 Million +4.38%
1997-12-31 $351.90 Million +23.52%
1996-12-31 $284.90 Million -0.07%
1995-12-31 $285.10 Million +8.12%
1994-12-31 $263.70 Million +1.46%
1993-12-31 $259.90 Million -4.69%
1992-12-31 $272.70 Million +7.74%
1991-12-31 $253.10 Million +18.71%
1990-12-31 $213.20 Million +15.62%
1989-12-31 $184.40 Million +18.74%
1988-12-31 $155.30 Million +17.65%
1987-12-31 $132.00 Million +29.92%
1986-12-31 $101.60 Million +42.10%
1985-12-31 $71.50 Million --

About Bio-Rad Laboratories Inc

NYSE:BIO-B USA Medical Devices
Market Cap
$1.57 Billion
Market Cap Rank
#6935 Global
#2144 in USA
Share Price
$309.37
Change (1 day)
+0.00%
52-Week Range
$255.54 - $309.37
All Time High
$818.60
About

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, pu… Read more